

Case Report on Antiphospholipid Antibody: Asherson Syndrome

**Ms. Rohini Moon¹, Ms. PriyaRewatkar², Aniket Pathade³, S. G. Kadwane⁴
, Miss. Kanchan Bokade⁵**

1] GNM 2nd year Florence Nightingale Training college of Nursing, Datta Meghe Institute of medical science (DU) Sawangi (M) Wardha

Email: rohinimoon23@gmail.com, Mob. No. 7774917239

2] Nursing Tutor, Florence Nightingale training college of nursing, Datta Meghe Institute of medical science (DU) Sawangi (M) Wardha

Email: priyarewatkar92@gmail.com, Mob. No. 90491215402

3] Research Scientist, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, Maharashtra, India.

4] Dept. of Electrical Engineering, Yeshwantrao Chavan College of Engineering, Nagpur. Email: psp4india16@gmail.com

5] Clinical Instructor, ShrimatiRadhikabaiMeghe Memorial College of Nursing, Email:kanchanbokade31@gmail.com

Abstract

Introduction: Thromboses in the arterial and venous systems characterize the antiphospholipid syndrome (APS).in the arterial, venous, or minor artery. as well as pregnancy morbidity, when antiphospholipid antibody titers are chronically increased. Since virtually any organ can be involved, the clinical presentation of APS is very varied. Abdominal manifestations are rare but may be life-threatening, and include Budd-Chiari Syndrome. We discuss a 26-year-old lady with primary APS brought to In March 2017, the Bangabandhu Sheikh Mujib Medical University (BSMMU) in Dhaka, Bangladesh, was established., on aspirin medication with ascites for which she had been receiving treatment for abdominal tuberculosis. Following clinical and laboratory evaluation, she was diagnosed as a case of Budd-Chiari Syndrome with portal hypertension and initiated treatment with warfarin.

Main Symptom and/ or important clinical finding: 25-year-old female admitted in Acharya vinoba Bhave Rural hospital on date 7-07-21 with the chief complaint of excessive breathing, weakness, fatigue, high blood pressure, headache blood clot etc. After physical examination & investigation doctor diagnose a case of Antiphospholipid antibody syndrome.

The main diagnoses, therapeutic interventions, and outcome: After physical examination and investigation doctor diagnose a case antiphospholipid antibody syndrome medical management was provided to the patient calcium & multivitamins supplementary was given for 7 days to enhance immune function. Tab. Valproate 1.5 mg. Anticoagulant. Tab. Atenolol 50mg. beta blocker. Tab. Vit. B12 for supplementary he was taking all treatment and outcome was good.

Conclusion: She was response to all medication as well as doctor treatment and her recovery was good.

Keyword: Aortic Thrombosis, Cerebral Infarcts, β 2 Glycoprotein 1 antibodies, Asherson's syndrome.

Introduction:

Antiphospholipid antibody syndrome (APLA) is a complicated illness that affects both men and women. that is rarely seen in everyday practice. APLA is a fairly varied disease with a wide range of clinical manifestations. [1,2,3] The prevalence Antiphospholipid antibody syndrome is defined as thromboembolic issues in the presence of regularly increased antiphospholipid antibody titers, and/or pregnancy morbidity. It can manifest in a variety of ways and affect any organ, and it is currently affecting most surgical and medical professions. [4,5,6]

Antiphospholipid syndrome causes microangiopathy, which affects small blood arteries throughout the body. The majority of individuals develops thrombocytopenia, with hemolytic Anaemia and disseminated intravascular coagulation occurring less commonly. Antibodies against the most prevalent antibodies linked to CAPS have been found as lupus anticoagulant and anticardiolipin. [7,8]

Clinical signs of APS are generally non-specific in the if there hasn't been a thrombotic incident, we recently saw a young man who had recently been diagnosed with hypertension and kidney disease. who had primary APS. His kidney biopsy findings, which revealed chronic microangiopathy features under electron microscopy, Multiple organ involvement and a triple-positive antiphospholipid antibody profile later validated the diagnosis of APS. [9,10] Anti-beta-2-glycoprotein 1 The most commonly implicated antibodies include antibodies, lupus anticoagulant, and anti-beta-2-glycoprotein 1 antibodies. and anticardiolipin antibody.1 and anticardiolipin antibody are the most often implicated antibodies. Anticoagulant activity is the primary function of these antibodies. These antibodies, contrary to their name, are linked to a Rather than a bleeding diathesis, this is a procoagulant disorder. Antiphospholipid (APL) bind to membrane plasma proteins. causes them to be activated chain reaction involving A prothrombotic state is caused by a combination of molecules are all involved in the healing process. While the popular belief is that thrombosis is the primary cause of APS, the importance of atherosclerosis should not be overlooked. [11,12]

Discovery of antibodies and our understanding of the syndrome's pathobiology We suggest a method to explain how anti-beta-2-glycoprotein I antibodies have been associated to a number of different diseases of clinical conditions. The occurrence of thrombo-embolic problems and Anti-phospholipid antibody (APLA) syndrome is defined as Pregnancy morbidity in the presence of anti-phospholipid antibody (APLA) syndrome titers that are constantly growing. It can affect any organ and has a wide range of clinical symptoms. making it a contemporary concern. in a wide range of surgical and medical specialties. The example of a 34-year-old woman with APLA syndrome who was diagnosed with the cerebral venous thrombosis and deep vein thrombosis of the left leg veins are discussed in this article. Three types of APLAs were found to be increased (IgG, IgM, and activated protein C). Other autoimmune or systemic disorders were not found in clinical or laboratory tests. R is being used to treat the patient. Antiphospholipid syndrome (APS) is an autoimmune disorder marked by hypercoagulability and the risk of thrombosis of all arterial bed segments of arterial and venous circulations, as well as pregnancy morbidity. Multiple organs are affected by this illness, which manifests itself in a variety of clinical symptoms. The most severe type, known as catastrophic antiphospholipid syndrome (CAPS), affects less than 1% of patients and is linked to multiple organ thrombosis. The most common signs are DVT, PE, and stroke are all examples of deep venous thrombosis. Anti-beta-2-glycoprotein 1 antibodies, lupus anticoagulant, and anticardiolipin antibody are all examples of anti-beta-2-glycoprotein 1 antibodies the most typically implicated antibodies. [12,13]

Recurrent thromboembolic events in the veins and/or the arteries, as well as pregnancy morbidity are all factors to consider. are clinical features of the syndrome. Aside from these clinical signs, the existence of a distinct set of autoantibodies directed against certain phospholipid-binding proteins is a need for the illness. The three laboratory tests evaluated in the updated version are antibodies against 2-glycoprotein I (a2GPI) and cardiolipin (aCL), as well as the lupus anticoagulant functional assay (LAC). [14,15]

Patient specific information: a 25-year-old female admitted in Acharya Vinoba Bhave Rural hospital on date 7-07-21 with the chief complaint of excessive breathing, weakness, fatigue, high blood pressure, headache, blood clot etc. After physical examination & investigation doctor diagnose a case of Antiphospholipid antibody syndrome.

Primary concern and symptoms of the patient: chief complaint of patient excessive breathing, weakness, fatigue, high blood pressure headache bloodclots. After physical examination & investigations doctor diagnose a case of antiphospholipid antibody syndrome as Asherson syndrome.

Relevant past interventions with outcome: History of antiphospholipid antibody syndrome 6 month back for which she was hospitalized. After CBC test, LFT test & other in Asherson syndrome was observed he took all support to treatment & his outcome was good.

Clinical finding: The patient was conscious & well oriented to time, place, date his body build was moderate & he had maintained good personal hygiene. Her weight 45 kg his in-milestone development the patient is anemic.

Timeline: 6 months ago, he was admitted in the hospital Antiphospholipid antibody syndrome is treated with this drug. He is currently being treated for antiphospholipid antibody syndrome. currently he was admitted for the treatment of antiphospholipid antibody syndrome calcium and multivitamins supplementary was given for 7 days. To enhancement function.

Diagnostic assessment: On the basis of the of patient's history collection, physical examination, CBS blood test investigation was also done WBC count (20,000/cumm) less than normal platelets count was less 1.57 lacs command hemoglobin was less 7.5 and other investigation was also done.

Diagnostic challenges: No any challenging during the diagnostic evaluation.

Diagnosis: After physical examination & investigation doctor diagnosed a case of antiphospholipid antibody Asherson syndrome.

Prognosis: was good.

Therapeutic interventions: Medical management was provided to the patient calcium & multivitamins supplementary was given for 7 days to enhance immune function. Tab. Valproate 1. 5mg. Anticoagulant. Tab. Atenolol 50mg. beta blocker. Tab. Vit. B12 for supplementary she was taking all treatment and outcome was good. No any change in restorative.

Follow-Up & Outcome:

Clinical & patient assessment Outcome:

Patient conditions was improved important check out investigation and other test results to preventing to progression of disease & trying to reserve any sign & symptoms doctor advice to follow up blood investigation & other examination to know the disease progression.

Interventions Adherence & Tolerability: patient took all prescribed medications regular. But sometimes he was refused to take medication. He also followed the dietician advised. Dietician was advised healthy food & rich in calcium & multivitamins supplementation. Her interventional adherence was satisfactory.

Nursing perspective: Monitor the vital signs of patient person hourly. Multifluid and electrolytes balance.

Discussion:

APS is a type of autoimmune disease that causes thrombosis in the arteries and veins, as well as recurrent foetal loss and thrombocytopenia. It was first discovered It was first discovered in people with SLE (systemic lupus erythematosus), which was later connected to other autoimmune disorders Primary APS is another name for this condition. which is a syndrome that can arise without any underlying disease. CAPS, a deadly variation of APS that affects about 1% of the population, was initially identified in 1992. (7) APS is a thrombotic autoimmune disease that manifests itself in a variety of ways. For the diagnosis of definite APS, at least one clinical and one laboratory criterion is required. [16]

Based on HIRA data, which is a statewide required insurance programme offered by the Korean government, this is the first nationwide population-based investigation of the incidence, prevalence, and related consequences of APS. In contrast to a prior population-based investigation, our findings revealed that the incidence rate of APS varied by gender and age group. Anionic phospholipids are antigenic bilaminar phospholipids that are found on the inner sides of membranes. Accessory proteins like beta-2 glycoprotein I, on the other hand, may help to speed up and stabilize the shift to hexagonal antigenic forms. Antiphospholipid antibodies are thought to be made up of a variety of proteins. of antiphospholipid I combination of antibodies and anti-beta-2 glycoprotein antibodies, Or I complex, or antibodies and anti-beta-2 glycoprotein antibodies against phospholipids exclusively. [16]

The phrase APLA syndrome refers to the clinical link between APLAs and a hypercoagulability syndrome. It's an autoimmune condition marked by thromboembolic issues and pregnant morbidity. Antibodies to are the most often identified subgroups of APLAs. Rather than clinical bleeding, Thromboembolic events have been associated to lupus anticoagulant antibodies. Both pro- and anti-coagulant pathways can be disrupted by APL. [15]

Sarcoidosis Expression Antiphospholipid antibody syndrome (APS), sarcoidosis, and systemic lupus erythematosus (SLE) are chronic immunological dysregulation illnesses. causes are unknown in the previous 60 years, only a few incidences of Individuals have been diagnosed with sarcoidosis and SLE. In this investigation, we present two cases with sarcoidosis and SLE that coexisted, with problems linked to Anticardiolipin antibodies were found in both cases. Clinical, serological, and pathological information are all available in each case confirmed the diagnoses, and both patients responded well to treatment. The relationship between sarcoidosis, SLE, and APS is unusual, and it can make treatment challenging. Thrombosis manifests itself DVT, pulmonary thromboembolism, and stroke are all examples of thromboembolism in people with APS. Valvular illness and intracardiac thrombus development are the most common cardiac symptoms of APS. Only 4% of the time does a myocardial infarction occur Autoimmune illnesses, such as Chronic inflammation is recognized to promote early atherosclerosis in Systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and other autoimmune illnesses and APS. While the role of APL antibodies in an etiology of thrombosis in APS is well understood, the existence of certain cardiovascular risk factors or medical conditions in these patients increases the risk of thrombosis. [17]

Conclusion: -Traditional cardiovascular risk factors have been shown to substantially enhance the risk of thrombosis and atherosclerosis time and time again. Due to the existence of Antibodies against APL and chronic inflammation, both of which lead to early atherosclerosis Thrombotic load is already high in APS patients. To prevent future endothelial and vascular damage, primary care physicians must be vigilant in identifying and actively managing conventional risk factors. To treat diabetes, hypertension, and obesity, Strict dietary and physical activity modifications are required. Furthermore, In the elderly, women, and diabetics, silent myocardial infarction is

prevalent Further more silent in the elderly, women, and diabetics. A common concern is myocardial infarction. Quitting smoking is another way to reduce the progression of atherosclerotic disease. To achieve improved patient outcomes, a multidisciplinary strategy combining primary care doctors, for coordinated management of these patients, hematologists and cardiologists are essential.

Reference:

1. Naik SN, Raghavendra Y. Antiphospholipid antibody syndrome-A case report. *Ayu.* 2017 Jan;38(1-2):62.
2. Luma HN, Doualla MS, Temfack E, Bagnaka SA, Mankaa EW, Fofung D. The antiphospholipid antibody syndrome: a case report. *International medical case reports journal.*
3. Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. *Case reports in hematology.* 2014 Oct 15;2014.
4. Tsiakas S, Skalioti C, Kotsi P, Boletis I, Marinaki S. Case of an unusual diagnosis of primary antiphospholipid syndrome with multiple clinical complications. *Oxford medical case reports.* 2020 Dec;2020(12): omaa117. Parsi M, Rai M, Swaab R. A
5. Rare Case of Catastrophic Antiphospholipid Antibody Syndrome: A Case Report and Review of Traditional Cardiovascular Risk Factors Implicated in Disease Occurrence. *Cureus.* 2020 Mar;12(3).
6. Durrani, O. M., Gordon, C., & Murray, P. I. (2002). Primary anti-phospholipid antibody syndrome (APS): current concepts. *Survey of ophthalmology*, 47(3), 215-238.
7. M. Hurtado-Sbordoni, N. Galeas, K. Bakirhan, K. Alexis, T. Elrafei, M. Hurtado-Sbordoni, N. Galeas, K. Bakirhan, K. Alexis, T. Elrafei, M. Hurtado-Sbordoni, N. Galeas, K. Bakirhan, K. Alexis, T. A case report and literature review of a 36-year-old woman who was treated with eculizumab for catastrophic antiphospholipid syndrome. *Hematology Case Reports*, published online October 15, 2014, is a journal that publishes case reports in the field of haematology.
8. Tsiakas S, Skalioti C, Kotsi P, Boletis I, Marinaki S. Case of an unusual diagnosis of primary antiphospholipid syndrome with multiple clinical complications. *Oxford medical case reports.* 2020 Dec;2020(12): omaa117.
9. Castañeda Ospina SA, Cardona Maya WD, Bueno Sánchez JC, Cadavid Jaramillo ÁP. Pregnancy outcome in women with antiphospholipid syndrome and alloimmunity: a case report. *Sao Paulo Medical Journal.* 2003; 121:248-50.
10. Naik SN, Raghavendra Y. Antiphospholipid antibody syndrome-A case report. *Ayu.* 2017 Jan;38(1-2):62.
11. Pashnina, I. A., Krivolapova, I. M., Fedotkina, T. V., Ryabkova, V. A., Cheresheva, M. V., Churilov, L. P., & Chereshev, V. A. (2021). Antinuclear autoantibodies in health: autoimmunity is not a synonym of autoimmune disease. *Antibodies*, 10(1), 9.
12. Mohammad, S., Bhute, A., Acharya, N., Acharya, S., 2020b. Moschcowitz syndrome or thrombotic thrombocytopenic purpura and antiphospholipid antibody syndrome as a rare cause of thrombocytopenia in pregnancy mimicking hemolysis, elevated liver enzymes, and low platelets syndrome in a patient with bad obstetric history: A diagnostic dilemma. *Journal of SAFOG* 12, 250–253. <https://doi.org/10.5005/jp-journals-10006-1791>
13. Abbafati, Cristiana, Kaja M. Abbas, Mohammad Abbasi, Mitra Abbasifard, Mohsen Abbasi-Kangevari, HedayatAbbastabar, Foad Abd-Allah, et al. “Five Insights from the Global Burden of Disease Study 2019.” *LANCET* 396, no. 10258 (October 17, 2020): 1135–59.
14. Abbafati, Cristiana, Kaja M. Abbas, Mohammad Abbasi, Mitra Abbasifard, Mohsen Abbasi-Kangevari, HedayatAbbastabar, Foad Abd-Allah, et al. “Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019.” *LANCET* 396, no. 10258 (October 17, 2020): 1204–22.
15. Franklin, Richard Charles, Amy E. Peden, Erin B. Hamilton, Catherine Bisignano, Chris D. Castle, Zachary Dingels V, Simon Hay I, et al. “The Burden of Unintentional Drowning: Global, Regional and National Estimates of Mortality from the Global Burden of Disease 2017 Study.” *INJURY PREVENTION* 26, no. SUPP_1, 1 (October 2020): 83–95. <https://doi.org/10.1136/injuryprev-2019-043484>.
16. James, Spencer L., Chris D. Castle, Zachary Dingels V, Jack T. Fox, Erin B. Hamilton, Zichen Liu, Nicholas L. S. Roberts, et al. “Estimating Global Injuries Morbidity and Mortality: Methods and Data Used in the Global Burden of Disease 2017 Study.” *INJURY PREVENTION* 26, no. SUPP_1, 1 (October 2020): 125–53. <https://doi.org/10.1136/injuryprev-2019-043531>.

17. James, Spencer L., Chris D. Castle, Zachary Dingels V, Jack T. Fox, Erin B. Hamilton, Zichen Liu, Nicholas L. S. Roberts, et al. "Global Injury Morbidity and Mortality from 1990 to 2017: Results from the Global Burden of Disease Study 2017." *INJURY PREVENTION* 26, no. SUPP_1, 1 (October 2020): 96–114. <https://doi.org/10.1136/injuryprev-2019-043494>.